## Appendix 18a: organisation of care GRADE tables

Case management versus treatment as usual (TAU)	2
Economic profiles	5
Stepped care versus minimal intervention	5

## Case management versus treatment as usual (TAU)

Quality assessment								Summary of findings					
Quanty				ment			No. of patients		Effect			Importance	
No. of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	Case management	TAU	Relative (95% CI)	Absolute	Quality	importance	
Number	of participants n	ion-abstinent - a	t 6-month follow	-up									
1	Randomised trials	No serious limitations	No serious inconsistency	No serious indirectness	Serious <sup>1</sup>	None		4 (10 (22 2%)	15/18 (83.3%)	(83.3%) RR 0.27	608 fewer per 1000 (from 292 fewer to 742 fewer)	⊕⊕⊕O	CRITICAL
							4/10 (22.2 %)	83.3%	(0.11 to 0.65)	608 fewer per 1000 (from 292 fewer to 741 fewer)	MODERATE	CKIIICAL	
Number	of participants n	ion-abstinent - a	t 12-month follov	v-up (RCT)									
1	Randomised trials	No serious limitations	No serious inconsistency	No serious indirectness	Serious <sup>2</sup>	None		16/18 (88.9%)	RR 0.69 (0.46 to 1.03)	276 fewer per 1000 (from 480 fewer to 27 more)	⊕⊕⊕O MODERATE	CRITICAL	
							11/18 (61.1%)	88.9%		276 fewer per 1000 (from 480 fewer to 27 more)			
Number	of participants n	on-abstinent - a	t 2-year follow-uj	o (non-RCT)									
1	Observational studies	No serious limitations	No serious inconsistency	No serious indirectness	Serious <sup>1</sup>	None	45/70 (64.3%)	49/52 (94.2%) 94.2%	RR 0.68 (0.57 to 0.82)		302 fewer per 1000 (from 170 fewer to 405 fewer)	⊕000	CRITICAL
							43/70 (64.3%)			301 fewer per 1000 (from 170 fewer to 405 fewer)	VERY LOW	CRITICAL	
Number	of participants n	ion-abstinent - a	t 3-year follow-uj	o (non-RCT)									
1	Observational studies	No serious limitations		No serious indirectness	Serious <sup>1</sup>	None		47/52 (90.4%)	RR 0.63	334 fewer per 1000 (from 190 fewer to 443 fewer)			
							40/70 (57.1%)	90.4%	(0.51 to 0.79)	(0.51 to	334 fewer per 1000 (from 190 fewer to 443 fewer)		CRITICAL

Number	of participants n	on-abstinent -	at 4-year follow-1	up (non-RCT)								
1	Observational studies	No serious limitations	No serious inconsistency	No serious indirectness	Serious <sup>1</sup>	None	26/20/51 49()	44/52 (84.6%)	RR 0.61 (0.47 to 0.78)	330 fewer per 1000 (from 186 fewer to 448 fewer)	+ OOO VERY LOW	
							36/70 (51.4%)	84.6%		330 fewer per 1000 (from 186 fewer to 448 fewer)		CRITICA
Number	of participants n	on-abstinent -	at 5-year follow-1	up (non-RCT)								
1	Observational studies	No serious limitations	No serious inconsistency	No serious indirectness	Serious <sup>1</sup>	None	32/70 (45.7%)	38/52 (73.1%)	RR 0.63	270 fewer per 1000 (from 110 fewer to 395 fewer)	⊕000	CRITICA
							32/70 (43.7%)	73.1%	(0.46 to 0.85)	270 fewer per 1000 (from 110 fewer to 395 fewer)	VERY LOW	CRITICAL
Drinkin	g frequency - me	an days of alco	hol intoxication (	Better indicated	by lower values	5)						
2	Observational studies	No serious limitations	No serious inconsistency	No serious indirectness	No serious imprecision	None	184	353	-	SMD 0.07 lower (0.25 lower to 0.11 higher)	⊕⊕OO LOW	CRITICAL
Drinkin	g frequency - day	ys any alcohol u	ise at 6-month fo	llow-up (Better i	indicated by low	er values)		•		-		
2	Randomised trials	No serious limitations	No serious inconsistency	No serious indirectness	No serious imprecision	None	286	255	-	SMD 0.1 lower (0.4 lower to 0.2 higher)	⊕⊕⊕⊕ HIGH	CRITICA
Drinkin	g frequency - day	s using alcoho	l since last interv	riew at 6-month f	follow-up (Bette	r indicated by l	ower values)					
1	Randomised trials	No serious limitations	No serious inconsistency	No serious indirectness	No serious imprecision	None	105	83	-	SMD 0.34 lower (0.63 to 0.05 lower)	⊕⊕⊕⊕ HIGH	CRITICA
Drinkin	g frequency - day	s drinking any	alcohol, in last 3	0 days, at 9-mon	th follow-up (Be	etter indicated	by lower values)					
1	Randomised trials	No serious limitations	No serious inconsistency	No serious indirectness	No serious imprecision	None	178	170	-	SMD 0.13 lower (0.34 lower to 0.08 higher)	⊕⊕⊕⊕ HIGH	CRITICA
Drinkin	g frequency - day	rs drinking any	alcohol, in last 3	0 days, at 12-mo	onth follow-up (I	Better indicated	by lower values)					
1	Randomised trials	No serious limitations	No serious inconsistency	No serious indirectness	No serious imprecision	None	108	85	-	SMD 0.21 lower (0.49 lower to 0.08 higher)	⊕⊕⊕⊕ HIGH	CRITICA
Drinkin	g frequency - day	s using alcoho	l since last interv	iew at 12-month	follow-up (Bett	er indicated by	lower values)					
	Randomised	No serious	No serious	No serious	No serious	None				SMD 0.3 lower (0.59	$\oplus \oplus \oplus \oplus$	

Drinking frequency - days drinking any alcohol, in last 30 days, at 18-month follow-up (Better indicated by lower values)												
			No serious inconsistency	No serious indirectness	No serious imprecision	None	108	85	-	SMD 0.33 lower (0.62 to 0.05 lower)	⊕⊕⊕⊕ HIGH	CRITICAL
Drinking	Drinking frequency - days using alcohol since last interview at 18-month follow-up (Better indicated by lower values)											
			No serious inconsistency	No serious indirectness	No serious imprecision	None	105	83	-	SMD 0.49 lower (0.78 to 0.2 lower)	⊕⊕⊕⊕ HIGH	CRITICAL

<sup>1</sup> RR reduction greater than 25% <sup>2</sup> 95% CI includes no effect. RR reduction greater than 25%

## **Economic profiles**

## Stepped care versus minimal intervention

Study & country	Limitations	Applicability	Other comments	Incremental cost (£)	Incremental effect (QALYs)	ICER (£/QALY)	Uncertainty
Drummond et al. 2009, UK	Minor limitations <sup>1</sup>	Directly applicable <sup>2</sup>	-	Unable to calculate <sup>3</sup>	Unable to calculate	Unable to calculate	98% probability of stepped-care intervention being cost effective at UK £20-30,000 threshold - based on 1000 bootstrap samples

<sup>&</sup>lt;sup>1</sup> Short time horizon; no formal synthesis of incremental costs and effectiveness.

<sup>&</sup>lt;sup>2</sup> Societal perspective including criminal justice costs.

<sup>&</sup>lt;sup>3</sup> Not possible to calculate ICER with data available. Authors did not report total costs over 6-month period.